Market openADR
Achilles Therapeutics/$ACHL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Achilles Therapeutics
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Ticker
$ACHL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
210
Website
ACHL Metrics
BasicAdvanced
$57M
-
-$1.66
1.32
-
Price and volume
Market cap
$57M
Beta
1.32
52-week high
$1.39
52-week low
$1.36
Financial strength
Current ratio
6.044
Quick ratio
5.839
Total debt to equity
3.51
Management effectiveness
Return on assets (TTM)
-30.17%
Return on equity (TTM)
-52.12%
Valuation
Price to book
0.55
Price to tangible book (TTM)
0.55
Price to free cash flow (TTM)
-0.875
Growth
Earnings per share change (TTM)
-12.21%
3-year earnings per share growth (CAGR)
-16.83%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Achilles Therapeutics stock?
Achilles Therapeutics (ACHL) has a market cap of $57M as of March 12, 2025.
What is the P/E ratio for Achilles Therapeutics stock?
The price to earnings (P/E) ratio for Achilles Therapeutics (ACHL) stock is 0 as of March 12, 2025.
Does Achilles Therapeutics stock pay dividends?
No, Achilles Therapeutics (ACHL) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Achilles Therapeutics dividend payment date?
Achilles Therapeutics (ACHL) stock does not pay dividends to its shareholders.
What is the beta indicator for Achilles Therapeutics?
Achilles Therapeutics (ACHL) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.